mail
versión imprimible
 
 

7th Neuropsychiatric Drug Development Summit

Evvnt Promotion / evvnt
-
24.09.2024 - 26.09.2024  Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
 
Temas de la conferencia
With Karuna's schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.
Organizador profesional (PCO)
Hanson Wade Group
Observaciones
URL:
Brochure: https://go.evvnt.com/2433814-3?pid=4832

Speakers: Aaron Koenig, Chief Medical Officer, Delix Therapeutics, Ariana Mullin, Director, Regulatory Affairs, Bristol Myers Squibb, and more
 

Información e inscripción:

https://go.evvnt.com/2433814-2?pid=4832
Ms. Erin Thomas
 
Categorías
Medicina General
Idioma
Inglés
Cuota del Congreso
Drug Developer Pricing - Conference + Workshop Day: USD 3597.00, Drug Developer Pricing - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + Workshop Day: USD 5197.00, Solution Provider Pricing - Conference Only: USD 3699.00
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

European Public Health Association (EUPHA)OÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Swiss Tropical and Public Health InstituteÖsterreichische Gesellschaft für Public HealthÖsterreichische Akademie der ÄrztenewTreeÄrztekammer für WienÄrzte der Welt